In this issue:
Cutaneous adverse events and survival with ICIs
Mogamulizumab for Sézary syndrome
Secukinumab every two weeks for psoriasis patients ≥90 kg
Long-term use of risankizumab for moderate-to-severe plaque psoriasis
5-year data for guselkumab for moderate-to-severe psoriasis
Brodalumab for plaque psoriasis after failure of an IL-17A blocker
Adalimumab therapy for hidradenitis suppurativa
Janus kinase 1 inhibitor for moderate-to-severe hidradenitis suppurativa
Patient’s perspective on dupilumab for atopic dermatitis
Please login below to download this issue (PDF)